艾滋病相关非霍奇金淋巴瘤患者的临床病理特征与生存分析
回顾性分析53例艾滋病相关非霍奇金淋巴瘤(ARL)患者临床资料,按1∶2配对以106例普通非霍奇金淋巴瘤(NHL)患者为对照。ARL组总生存时间显著短于对照组,接受抗NHL治疗者1年总生存率低于对照组,但2、3、5年总生存率差异无统计学意义。
要点
- ARL多见于青壮年,平均年龄43(11~67)岁,男女比约4∶1。
- ARL组总生存时间(6.0±1.3)个月,显著短于对照组(48.0±10.0)个月(P<0.05)。
- 抗HIV治疗联合CHOP方案抗NHL治疗能显著改善ARL患者预后。
核心结论
- ARL多见于青壮年,1年内病死率高。
- 抗HIV治疗联合抗NHL治疗能显著改善ARL患者预后。
- CHOP方案可能更适合ARL患者。
研究设计与样本
- 回顾性分析53例在武汉大学中南医院诊断并接受诊疗的ARL患者临床资料。
- 按1∶2配对以106例普通NHL患者为对照组。
- 采用SPSS 13.0软件进行统计分析,Kaplan-Meier法评估生存概率。
主要发现
- ARL患者平均年龄43(11~67)岁,男女比约4∶1,诊断NHL时CD4(+)T细胞中位数为(146±20)个/μl。
- Ann Arbor分期Ⅲ~Ⅳ期者占52.8%,血清乳酸脱氢酶升高者约54.7%,国际预后指数高危组占64.2%。
- 53例中B细胞来源47例(88.7%),T细胞来源6例(11.3%),弥漫大B细胞淋巴瘤为主要组织学亚型。
- ARL组总生存时间(6.0±1.3)个月,显著短于对照组(48.0±10.0)个月(P<0.05)。
- 接受抗NHL治疗者中,ARL组(33例)与对照组(100例)总生存时间分别为(48.0±10.9)个月和(77.0±11.1)个月,差异无统计学意义(P=0.816);ARL组1年总生存率低于对照组(60.6%对83.0%,P<0.05),2年(53.5%对60.5%)、3年(48.1%对45.9%)、5年(39.1%对27.5%)总生存率差异均无统计学意义(P值均>0.05)。
关键数值与推荐
- 33例(62.3%)接受抗HIV治疗联合抗NHL的CHOP化疗方案。
- 8例(15.1%)仅接受抗HIV治疗。
- 12例(22.6%)要求姑息治疗。
临床怎么用
- 抗HIV治疗联合CHOP方案抗NHL治疗能显著改善ARL患者预后,CHOP方案可能更适合ARL患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To analyze the clinical characteristics, pathological features and survival of patients with AIDS related non-Hodgkin's lymphoma (ARL) . Methods: The clinical data of 53 ARL cases diagnosed and received care at Zhongnan hospital of Wuhan University were retrospectively studied, and 106 controls were enrolled as control group according to 1∶2 for paired cases and control. SPSS 13.0 package was used for statistical analysis. Kaplan-Meier was applied to assess the survival probability. Results: The mean age of patients with ARL was 43 (11-67) years. Male versus female was approximately 4∶1. The median CD4(+) T cell count was (146±20) /ml. The Ann Arbor clinical classification showed that 52.8% of the cases were of stage Ⅲ and Ⅳ. Approximately 54.7% of the patients had elevated serum lactate dehydrogenase (LDH) . According to international prognosis index score, 64.2% of the patients were in high risk group. Diffuse large B-cell lymphoma (DLBCL) was the predominant histological subtype. Among 53 cases, 33 cases (62.3%) received combination of anti-HIV therapy and anti-NHL (CHOP) chemotherapy regimen, 8 cases (15.1%) only received anti-HIV therapy, and 12 cases (22.6%) asked for alleviative treatment. Median survival time was (6.0±1.3) months for ARL cases versus (48.0±10.0) months for controls (P<0.05) . After eliminating cases who did not receive anti-lymphoma treatment, ARL cases showed a lower 1-year OS rates than control group (60.6% versus 83.0%) , but no difference about 2-, 3- and 5-year OS rates (53.5% versus 60.5%, 48.1% versus 45.9%, and 39.1% versus 27.5%, respectively) . Conclusions: ARL is more common in young adults; one-year mortality rate is high. Anti-HIV therapy combined with anti-NHL therapy could significantly improve the prognosis of ARL patients. CHOP regimen may be more suitable for ARL patients. 目的:分析艾滋病相关非霍奇金淋巴瘤(ARL)患者的临床特征及生存状态。 方法:回顾性分析53例ARL患者的临床资料,按1∶2随机配对对照研究方法,以106例普通非霍奇金淋巴瘤(NHL)患者为对照,比较两组患者的生存率。 结果: 53例ARL患者的平均年龄为43(11~67)岁,诊断NHL时CD4(+)T细胞中位数为(146±20)个/μl。53例患者中B细胞来源者47例(88.7%),T细胞来源者6例(11.3%)。Ann Arbor分期Ⅲ~Ⅳ期者占52.8%(28/53);IPI评分中高危组和高危组患者比例分别为45.3%(24/53)和18.9%(10/53)。ARL诊断后放弃治疗者占37.7%(20/53),抗HIV治疗联合放化疗者占62.3%(33/53)。抗NHL治疗采用CHOP(环磷酰胺、长春新碱、表阿霉素、泼尼松)方案。ARL组患者的总生存(OS)时间显著短于对照组[(6.0±1.3)对(48.0±10.0)个月,P<0.05]。接受抗NHL治疗的患者中,ARL组(33例)和对照组(100例)患者的OS时间差异无统计学意义[(48.0±10.9)对(77.0±11.1)个月,P=0.816];ARL组患者1年OS率低于对照组(60.6%对83.0%,P<0.05),但两组患者的2年(53.5%对60.5%)、3年(48.1%对45.9%)和5年(39.1%对27.5%)OS率差异均无统计学意义(P值均>0.05)。 结论: ARL多见于青壮年,1年内病死率高,抗HIV治疗联合CHOP方案抗NHL治疗能显著改善ARL患者预后。.
引用
- Sun KY, Gui XE, Deng D, et al. [Clinicpathological features and survival of patients with AIDS related non-Hodgkin's lymphoma]. Zhonghua Xue Ye Xue Za Zhi. 2017. PMID: 28279031. doi:10.3760/cma.j.issn.0253-2727.2017.02.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。